RFP | August 8, 2014
U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute announces the availability of funding for implementation of the New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers (U01) Grant. The purpose of this grant is to identify targets whose inhibition would induce synthetic lethality in cancers dependent on the expression of mutant KRas alleles. Contractors should refer to Section VII, Agency Contacts, in the RFP for information regarding each Institute's grants management contact for this program . . .